| Literature DB >> 24364030 |
Liwei Tan1, Xu Xu1, Jia Song1, Feng Luo1, Zhiyong Qian1.
Abstract
A kind of chemically cross-linked pH-sensitive hydrogels based on methoxyl poly(ethylene glycol)-poly(caprolactone)-acryloyl chloride (MPEG-PCL-AC, PECA), poly(ethylene glycol) methyl ether methacrylate (MPEGMA, MEG), N,N-methylenebisacrylamide (BIS), and itaconic acid (IA) were prepared without using any organic solvent by heat-initiated free radical method. The obtained macromonomers and hydrogels were characterized by ¹H NMR and FT-IR, respectively. Morphology study of hydrogels was also investigated in this paper, and it showed that the hydrogels had good pH-sensitivity. The acute toxicity test and histopathological study were conducted in BALB/c mice. The results indicated that the maximum tolerance dose of the hydrogel was higher than 10,000 mg/kg body weight. No morality or signs of toxicity were observed during the whole 7-day observation period. Compared to the control groups, there were no important adverse effects in the variables of hematology routine test and serum chemistry analysis both in male or female treatment group. Histopathological study also did not show any significant lesions, including heart, liver, lung, spleen, kidney, stomach, intestine, and testis. All the results demonstrated that this hydrogel was nontoxic after gavage. Thus, the hydrogel might be the biocompatible potential candidate for oral drug delivery system.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24364030 PMCID: PMC3864077 DOI: 10.1155/2013/239838
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
The hydrogel prepared in this work.
| PECA : MPEGMA : IA | BIS content (wt%) | IA Content (wt%) |
|---|---|---|
| 3 : 3 : 4 | 8.3 | 16.6 |
Figure 1Synthesis scheme of P(ECA-IA-MEG) hydrogel.
Figure 2Direct observation of synthesis of the P(ECA-IA-MEG) hydrogel. (a) Mixture solution of PECA, IA, MPEGMA, BIS, and APS. (b) Obtained hydrogel after being heated at 37°C for 4 hrs.
Figure 31H NMR spectrum of PECA macromonomer (in CDCl3).
Figure 4FT-IR spectra of PECA and P(ECA-IA-MEG) hydrogels.
Figure 5SEM observation of P(ECA-IA-MEG) in pH 1.2 (a) and pH 6.8 (b).
Swelling behavior of hydrogels in aqueous medium with pH 1.2 and pH 7.4 at 37°C.
| Time (h) | Swelling Radio (%) | |
|---|---|---|
| pH 1.2 | pH 7.4 | |
| 1 | 210 ± 3 | 341 ± 16 |
| 2 | 205 ± 10 | 355 ± 20 |
| 4 | 204 ± 6 | 383 ± 26 |
| 8 | 202 ± 5 | 402 ± 11 |
| 24 | 200 ± 3 | 426 ± 14 |
| 48 | 195 ± 4 | 460 ± 12 |
| 72 | 192 ± 3 | 480 ± 15 |
Toxicity signs not observed in BALB/c mice treated with P(ECA-IA-MEG) hydrogel.
| Motor activities | Restlessness, hyperactivity, and phonation |
| Symptoms of nervous system | Tail erect, tremble, spasm, movement disorder, and gesture abnormal |
| Symptoms of autonomic Nervous system | Protrusion of eyeballs, salivation, weep, urination, diarrhea, hair bristled up, and discoloration, dyspnea |
| mortality | Death |
Figure 6Mice body weight of each group during the observation period.
Hematology routine test of acute oral toxicity test.
| Female control group | Female treatment group | Male control group | Male treatment group | |
|---|---|---|---|---|
| WBC (109/L) | 6.01 ± 1.10 | 4.45 ± 0.59* | 3.86 ± 0.69 | 4.06 ± 0.50 |
| RBC (1012/L) | 11.13 ± 0.51 | 11.36 ± 0.39 | 11.11 ± 0.37 | 11.33 ± 0.38 |
| HGB (g/L) | 149.57 ± 5.47 | 152.63 ± 3.29 | 145.57 ± 3.95 | 151.50 ± 6.00 |
| HCT (%) | 58.17 ± 0.89 | 59.85 ± 1.53 | 57.30 ± 0.88 | 61.25 ± 1.77* |
| PLT (109/L) | 537.43 ± 108.23 | 666.38 ± 121.95 | 635.86 ± 56.57 | 666.38 ± 48.92 |
| MCV (fL) | 51.77 ± 1.18 | 52.33 ± 0.93 | 52.79 ± 0.90 | 53.84 ± 0.80 |
| MCH (pg) | 13.37 ± 0.31 | 13.36 ± 0.39 | 13.09 ± 0.38 | 13.31 ± 0.25 |
| MCHC (g/L) | 258.14 ± 3.72 | 255.38 ± 6.12 | 247.71 ± 4.92 | 247.38 ± 4.37 |
| RDW (%CV) | 16.89 ± 2.98 | 17.34 ± 0.92 | 17.31 ± 0.80 | 17.53 ± 0.70 |
| MPV (fL) | 5.53 ± 0.68 | 5.80 ± 0.55 | 5.39 ± 0.47 | 5.70 ± 0.25 |
| PDW (%) | 13.54 ± 0.81 | 14.77 ± 0.81 | 14.05 ± 0.79 | 15.06 ± 0.87 |
*P ≤ 0.05 compared to control group.
Serum chemistry analysis of acute oral toxicity test.
| Female control group | Female treatment group | Malecontrol group | Male treatment group | |
|---|---|---|---|---|
| ALB | 35.61 ± 1.57 | 35.00 ± 0.76 | 34.07 ± 1.35 | 34.34 ± 1.13 |
| ALP | 220.57 ± 16.24 | 236.38 ± 29.60 | 225.00 ± 29.30 | 206.00 ± 15.89 |
| ALT | 51.86 ± 18.77 | 43.75 ± 6.23 | 42.43 ± 3.21 | 42.13 ± 4.58 |
| AST | 113 ± 14.60 | 109.38 ± 12.64 | 102.00 ± 26.88 | 100.88 ± 19.11 |
| BUN | 9.01 ± 0.55 | 10.02 ± 1.10* | 9.89 ± 1.47 | 9.45 ± 0.99 |
| CREA | 1.86 ± 1.46 | 2.33 ± 1.06* | 2.43 ± 1.51 | 2.90 ± 0.76 |
| GLU | 3.61 ± 0.56 | 3.98 ± 0.54 | 5.37 ± 1.34 | 5.32 ± 0.88 |
| TBIL | 0.07 ± 0.19 | 0.27 ± 0.24 | 0.37 ± 0.33 | 0.21 ± 0.22 |
| TP | 62.54 ± 3.37 | 60.78 ± 1.89 | 60.31 ± 2.46 | 61.44 ± 2.00 |
*P ≤ 0.05 compared to control group.
Figure 7Photograph of mice cardiac muscle, liver, spleen, lung, kidney, stomach, duodenum, jejunum, ileum, colon, and testes after oral administration of P(ECA-IA-MEG) hydrogel (40x), ((b), (d), (f), (h), (j), (l), (n), (p), (r), (t), (v)) and of the control group ((a), (c), (e), (g), (i), (k), (m), (o), (q), (s), (u)).